Free Cash Flow to Equity (FCFE)
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
An analysis of the financial performance from 2016 to 2021 reveals a divergence between operational cash generation and the cash available to equity holders. While operating cash flows demonstrate a consistent upward trajectory, free cash flow to equity exhibits significant volatility, suggesting that non-operational financing activities and capital expenditures have heavily influenced the final cash position available to shareholders.
- Net Cash Provided by Operating Activities
- A steady and positive growth trend is observed in operational cash generation. Starting at 2,559 million US$ in 2016, the figure rose consistently each year, reaching 4,647 million US$ by 2021. This represents a substantial increase in the core ability of the business to generate cash from its primary operations over the six-year period.
- Free Cash Flow to Equity (FCFE) Volatility
- FCFE demonstrates extreme fluctuations that do not align with the steady growth of operating cash flows. A significant anomaly occurred in 2017, where FCFE spiked to 9,105 million US$, a value far exceeding the operating cash flow of 2,550 million US$ for the same period. This suggests a major non-operational cash inflow, such as significant new debt issuance or the sale of assets. Subsequently, FCFE declined sharply, reaching a low of 338 million US$ in 2019, before recovering to 3,173 million US$ by 2021.
- Operational Cash Flow and FCFE Divergence
- The lack of correlation between the steady increase in operating cash and the erratic movement of FCFE indicates that capital expenditure and net borrowing have been the primary drivers of equity cash flow. The sharp contraction in FCFE during 2019, despite an increase in operating cash to 3,330 million US$, implies a period of aggressive capital investment or substantial debt repayment. By 2021, the alignment improved, with FCFE reaching 3,173 million US$, reflecting a stronger conversion of operating cash into equity value.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Price to FCFE Ratio, Current
| No. shares of common stock outstanding | 285,064,629 |
| Selected Financial Data (US$) | |
| Free cash flow to equity (FCFE) (in millions) | 3,173) |
| FCFE per share | 11.13 |
| Current share price (P) | 259.64 |
| Valuation Ratio | |
| P/FCFE | 23.33 |
| Benchmarks | |
| P/FCFE, Competitors1 | |
| Abbott Laboratories | 30.22 |
| Elevance Health Inc. | 22.40 |
| Intuitive Surgical Inc. | 58.46 |
| Medtronic PLC | 26.20 |
| UnitedHealth Group Inc. | 20.03 |
| P/FCFE, Sector | |
| Health Care Equipment & Services | 18.22 |
| P/FCFE, Industry | |
| Health Care | 26.10 |
Based on: 10-K (reporting date: 2021-09-30).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 284,023,582 | 290,031,363 | 270,459,892 | 268,257,940 | 227,978,328 | 212,319,588 | |
| Selected Financial Data (US$) | |||||||
| Free cash flow to equity (FCFE) (in millions)2 | 3,173) | 969) | 338) | 3,060) | 9,105) | 614) | |
| FCFE per share3 | 11.17 | 3.34 | 1.25 | 11.41 | 39.94 | 2.89 | |
| Share price1, 4 | 244.46 | 227.47 | 260.40 | 242.04 | 224.23 | 168.48 | |
| Valuation Ratio | |||||||
| P/FCFE5 | 21.88 | 68.08 | 208.37 | 21.22 | 5.61 | 58.26 | |
| Benchmarks | |||||||
| P/FCFE, Competitors6 | |||||||
| Abbott Laboratories | 24.52 | — | — | — | — | — | |
| Elevance Health Inc. | 11.07 | — | — | — | — | — | |
| Intuitive Surgical Inc. | 58.39 | — | — | — | — | — | |
| Medtronic PLC | 38.91 | — | — | — | — | — | |
| UnitedHealth Group Inc. | 20.11 | — | — | — | — | — | |
| P/FCFE, Sector | |||||||
| Health Care Equipment & Services | 22.14 | — | — | — | — | — | |
| P/FCFE, Industry | |||||||
| Health Care | 17.94 | — | — | — | — | — | |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 Data adjusted for splits and stock dividends.
3 2021 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 3,173,000,000 ÷ 284,023,582 = 11.17
4 Closing price as at the filing date of Becton, Dickinson & Co. Annual Report.
5 2021 Calculation
P/FCFE = Share price ÷ FCFE per share
= 244.46 ÷ 11.17 = 21.88
6 Click competitor name to see calculations.
The valuation metrics between 2016 and 2021 exhibit significant volatility, primarily driven by erratic swings in Free Cash Flow to Equity (FCFE) per share rather than share price fluctuations.
- Share Price Performance
- A general upward trajectory in share price is observed from 2016 to 2019, increasing from 168.48 US$ to a peak of 260.40 US$. A moderate correction occurred in 2020, with the price dropping to 227.47 US$, followed by a recovery to 244.46 US$ by 2021.
- FCFE per Share Volatility
- Cash flow available to equity shareholders shows extreme inconsistency throughout the period. An anomalous peak is recorded in 2017 at 39.94 US$, which preceded a sharp contraction to 11.41 US$ in 2018 and a significant low of 1.25 US$ in 2019. FCFE per share subsequently improved, reaching 11.17 US$ by the end of the analyzed period in 2021.
- P/FCFE Ratio Interpretation
- The P/FCFE ratio displays hypersensitivity to the volatility of the FCFE denominator. The ratio reached an extreme high of 208.37 in 2019, directly correlating with the collapse in FCFE per share. Conversely, the ratio reached its lowest point of 5.61 in 2017 during the peak of cash flow generation. By 2021, the ratio normalized to 21.88, mirroring the 21.22 level observed in 2018, which indicates a stabilization of the relationship between market price and equity cash flows.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?